Evidence map›Paper›PMID 41539563›Full record

ArticleThe Journal of biological chemistry2026

ARF6 controls VSMC phenotypic switching upon lipid stimulation to promote inflammatory signaling contributing to the progression of atherosclerosis.

Émilie Fiola-Masson, Shirley Campbell, Véronique Laplante, Rania Lejri, Yasunori Kanaho, Jean-François Gauchat, Marc J Servant, Audrey Claing

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Émilie Fiola-MassonDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. Electronic address: emilie.fiola.masson@umontreal.ca.
Shirley CampbellDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Véronique LaplanteDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Rania LejriDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Yasunori KanahoDepartment of Physiological Chemistry, Faculty of Medical Sciences and Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Jean-François GauchatDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Marc J ServantFaculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.
Audrey ClaingDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular smooth muscle cells (VSMCs) play a pivotal role in the development and progression of atherosclerosis. Traditionally viewed as contractile cells that maintain vascular tone and structure, VSMCs undergo phenotypic switching in response to atherogenic stimuli, such as high circulating levels of LDL, thus adopting synthetic, osteogenic, or macrophage-like phenotypes. This plasticity contributes to plaque formation, extracellular matrix remodeling, and inflammatory signaling. We have previously shown that ADP-ribosylation factor 1, a small GTP-binding protein, regulates the expression and function of actin, which is important for maintaining the contractile phenotype of VSMCs. However, the role of ARF6 in phenotypic switching remains to be elucidated. Here, we demonstrate that ARF6 knockdown in human aortic smooth muscle cells reduced lipid uptake through alterations in the expression of scavenger receptors (lectin-like oxidized low-density lipoprotein receptor-1, macrophage scaverger receptor 1), cytokine production (IL-6) as well as the modulation of inflammatory markers and pathways (adhesion molecules, PI3K, NF-kB, p38). To confirm our findings in an in vivo setting, we engineered a novel conditional smooth muscle cell-specific ARF6 KO mouse in an atheroprone background (Acta2-Cre-ERT2

Indexed as

ADP-Ribosylation FactorsAtherosclerosisInflammationMuscle, Smooth, VascularMyocytes, Smooth MuscleADP-Ribosylation Factor 6AnimalsCells, CulturedDisease ProgressionHumansMiceMice, Inbred C57BLMice, KnockoutPhenotypeSignal TransductionADP-Ribosylation Factor 6ADP-Ribosylation FactorsARF6 protein, humanArf6 protein, mouseADP ribosylation factor (ARF)foam cellsgene knockoutinflammationlipid uptakephenotypic switchingtransgenic micevascular smooth muscle cells

Identifiers

PMID41539563
PMCPMC12876588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.